Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
JAMA Netw Open. 2023 Sep 5;6(9):e2335728. doi: 10.1001/jamanetworkopen.2023.35728.
Efforts to quantify the burden of SARS-CoV-2-associated sepsis have been limited by inconsistent definitions and underrecognition of viral sepsis.
To describe the incidence and outcomes of SARS-CoV-2-associated sepsis vs presumed bacterial sepsis using objective electronic clinical criteria.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included adults hospitalized at 5 Massachusetts hospitals between March 2020 and November 2022.
SARS-CoV-2-associated sepsis was defined as a positive SARS-CoV-2 polymerase chain reaction test and concurrent organ dysfunction (ie, oxygen support above simple nasal cannula, vasopressors, elevated lactate level, rise in creatine or bilirubin level, and/or decline in platelets). Presumed bacterial sepsis was defined by modified US Centers for Disease Control and Prevention adult sepsis event criteria (ie, blood culture order, sustained treatment with antibiotics, and organ dysfunction using identical thresholds as for SARS-CoV-2-associated sepsis).
Trends in the quarterly incidence (ie, proportion of hospitalizations) and in-hospital mortality for SARS-CoV-2-associated and presumed bacterial sepsis were assessed using negative binomial and logistic regression models.
This study included 431 017 hospital encounters from 261 595 individuals (mean [SD] age 57.9 [19.8] years, 241 131 (55.9%) females, 286 397 [66.5%] from academic hospital site). Of these encounters, 23 276 (5.4%) were from SARS-CoV-2, 6558 (1.5%) had SARS-CoV-2-associated sepsis, and 30 604 patients (7.1%) had presumed bacterial sepsis without SARS-CoV-2 infection. Crude in-hospital mortality for SARS-CoV-2-associated sepsis declined from 490 of 1469 (33.4%) in the first quarter to 67 of 450 (14.9%) in the last (adjusted odds ratio [aOR], 0.88 [95% CI, 0.85-0.90] per quarter). Crude mortality for presumed bacterial sepsis was 4451 of 30 604 patients (14.5%) and stable across quarters (aOR, 1.00 [95% CI, 0.99-1.01]). Medical record reviews of 200 SARS-CoV-2-positive hospitalizations confirmed electronic health record (EHR)-based SARS-CoV-2-associated sepsis criteria performed well relative to sepsis-3 criteria (90.6% [95% CI, 80.7%-96.5%] sensitivity; 91.2% [95% CI, 85.1%-95.4%] specificity).
In this retrospective cohort study of hospitalized adults, SARS-CoV-2 accounted for approximately 1 in 6 cases of sepsis during the first 33 months of the COVID-19 pandemic. In-hospital mortality rates for SARS-CoV-2-associated sepsis were high but declined over time and ultimately were similar to presumed bacterial sepsis. These findings highlight the high burden of SARS-CoV-2-associated sepsis and demonstrate the utility of EHR-based algorithms to conduct surveillance for viral and bacterial sepsis.
由于 SARS-CoV-2 相关脓毒症的定义不一致以及对病毒性脓毒症的认识不足,因此对其负担进行量化的努力受到了限制。
使用客观的电子临床标准描述 SARS-CoV-2 相关脓毒症与推定细菌性脓毒症的发生率和结局。
设计、地点和参与者:这项回顾性队列研究纳入了 2020 年 3 月至 2022 年 11 月期间在马萨诸塞州的 5 家医院住院的成年人。
SARS-CoV-2 相关脓毒症的定义是 SARS-CoV-2 聚合酶链反应检测呈阳性和同时出现器官功能障碍(即需要高于简单鼻导管的氧气支持、血管加压药、升高的乳酸水平、肌酐或胆红素水平升高和/或血小板减少)。推定细菌性脓毒症的定义是根据美国疾病控制与预防中心的成人脓毒症事件标准进行修改的(即血培养订单、持续使用抗生素治疗以及使用与 SARS-CoV-2 相关脓毒症相同的阈值进行的器官功能障碍)。
使用负二项式和逻辑回归模型评估 SARS-CoV-2 相关和推定细菌性脓毒症在每季度(即住院比例)的发生率和院内死亡率趋势。
这项研究包括了 261595 名个体的 431017 次住院治疗(平均[标准差]年龄为 57.9[19.8]岁,241131 名[55.9%]女性,286397 名[66.5%]来自学术医院)。在这些住院治疗中,有 23276 例(5.4%)是 SARS-CoV-2 感染,6558 例(1.5%)为 SARS-CoV-2 相关脓毒症,30604 例(7.1%)为没有 SARS-CoV-2 感染的推定细菌性脓毒症。SARS-CoV-2 相关脓毒症的院内死亡率从第 1 季度的 1469 例中的 490 例(33.4%)下降到最后一个季度的 450 例中的 67 例(调整后的优势比[OR],每季度 0.88[95%CI,0.85-0.90])。推定细菌性脓毒症的死亡率为 30604 例患者中的 4451 例(14.5%),且在各季度之间保持稳定(OR,1.00[95%CI,0.99-1.01])。对 200 例 SARS-CoV-2 阳性住院患者的病历审查证实,基于电子健康记录(EHR)的 SARS-CoV-2 相关脓毒症标准与脓毒症-3 标准相比表现良好(敏感性 90.6%[95%CI,80.7%-96.5%];特异性 91.2%[95%CI,85.1%-95.4%])。
在这项 COVID-19 大流行的前 33 个月期间,对住院成年人的回顾性队列研究中,SARS-CoV-2 约占脓毒症病例的 1/6。SARS-CoV-2 相关脓毒症的院内死亡率很高,但随着时间的推移而下降,最终与推定细菌性脓毒症相似。这些发现强调了 SARS-CoV-2 相关脓毒症的高负担,并证明了基于 EHR 的算法在监测病毒性和细菌性脓毒症方面的实用性。